These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 9647551

  • 1. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
    Meriggiola MC, Bremner WJ, Costantino A, Di Cintio G, Flamigni C.
    Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551
    [Abstract] [Full Text] [Related]

  • 2. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [Abstract] [Full Text] [Related]

  • 3. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive.
    Meriggiola MC, Bremner WJ, Paulsen CA, Valdiserri A, Incorvaia L, Motta R, Pavani A, Capelli M, Flamigni C.
    J Clin Endocrinol Metab; 1996 Aug; 81(8):3018-23. PubMed ID: 8768868
    [Abstract] [Full Text] [Related]

  • 4. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM.
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [Abstract] [Full Text] [Related]

  • 5. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM, Gow SM, Wu FC.
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [Abstract] [Full Text] [Related]

  • 6. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L, Bhasin S, Salameh W, Steiner B, Peterson M, Sokol RZ, Rivier J, Vale W, Swerdloff RS.
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [Abstract] [Full Text] [Related]

  • 7. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM.
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [Abstract] [Full Text] [Related]

  • 8. An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men.
    Meriggiola MC, Bremner WJ, Costantino A, Pavani A, Capelli M, Flamigni C.
    Fertil Steril; 1997 Nov; 68(5):844-50. PubMed ID: 9389813
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
    Guerin JF, Rollet J.
    Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
    [Abstract] [Full Text] [Related]

  • 10. Use of low-dosage oral cyproterone acetate as a male contraceptive.
    Wang C, Yeung KK.
    Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091
    [Abstract] [Full Text] [Related]

  • 11. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [Abstract] [Full Text] [Related]

  • 12. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ.
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [Abstract] [Full Text] [Related]

  • 13. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men.
    Moltz L, Römmler A, Post K, Schwartz U, Hammerstein J.
    Contraception; 1980 Apr; 21(4):393-413. PubMed ID: 6771095
    [Abstract] [Full Text] [Related]

  • 14. Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen.
    Meriggiola MC, Costantino A, Bremner WJ, Morselli-Labate AM.
    J Androl; 2002 Apr; 23(5):684-90. PubMed ID: 12185103
    [Abstract] [Full Text] [Related]

  • 15. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
    Anderson RA, Wallace AM, Wu FC.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
    [Abstract] [Full Text] [Related]

  • 16. Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men.
    Pangkahila W.
    Int J Androl; 1991 Aug; 14(4):248-56. PubMed ID: 1831798
    [Abstract] [Full Text] [Related]

  • 17. Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial.
    Zitzmann M, Rohayem J, Raidt J, Kliesch S, Kumar N, Sitruk-Ware R, Nieschlag E.
    Andrology; 2017 May; 5(3):516-526. PubMed ID: 28189123
    [Abstract] [Full Text] [Related]

  • 18. Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men.
    Meriggiola MC, Costantino A, Cerpolini S, Bremner WJ, Huebler D, Morselli-Labate AM, Kirsch B, Bertaccini A, Pelusi C, Pelusi G.
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5818-26. PubMed ID: 14671175
    [Abstract] [Full Text] [Related]

  • 19. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM, Nashan D, Hubert W, Nieschlag E.
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [Abstract] [Full Text] [Related]

  • 20. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
    Pavlou SN, Brewer K, Farley MG, Lindner J, Bastias MC, Rogers BJ, Swift LL, Rivier JE, Vale WW, Conn PM.
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.